

SHORT REPORT

Open Access



Knockdown of *myorg* leads to brain calcification in zebrafish

Miao Zhao[†], Xiao-Hong Lin[†], Yi-Heng Zeng[†], Hui-Zhen Su, Chong Wang, Kang Yang, Yi-Kun Chen, Bi-Wei Lin, Xiang-Ping Yao* and Wan-Jin Chen* 

Abstract

Primary familial brain calcification (PFBC) is a neurogenetic disorder characterized by bilateral calcified deposits in the brain. We previously identified that *MYORG* as the first pathogenic gene for autosomal recessive PFBC, and established a *Myorg*-KO mouse model. However, *Myorg*-KO mice developed brain calcifications until nine months of age, which limits their utility as a facile PFBC model system. Hence, whether there is another typical animal model for mimicking PFBC phenotypes in an early stage still remained unknown. In this study, we profiled the mRNA expression pattern of *myorg* in zebrafish, and used a morpholino-mediated blocking strategy to knockdown *myorg* mRNA at splicing and translation initiation levels. We observed multiple calcifications throughout the brain by calcein staining at 2–4 days post-fertilization in *myorg*-deficient zebrafish, and rescued the calcification phenotype by replenishing *myorg* cDNA. Overall, we built a novel model for PFBC via knockdown of *myorg* by antisense oligonucleotides in zebrafish, which could shorten the observation period and replenish the *Myorg*-KO mouse model phenotype in mechanistic and therapeutic studies.

Keywords: Primary familial brain calcification, *Myorg*, Zebrafish, Antisense oligo, Knockdown

Introduction

Brain calcification is often observed in the elderly. Its prevalence is higher in individuals with Parkinson's disease, Alzheimer's disease, and Down's syndrome [1, 2]. The prevalence of brain calcification is estimated to be 6.6 per 1000 or higher in China [3]. Primary familial brain calcification (PFBC), also known as idiopathic basal ganglia calcification (IBGC) or Fahr's disease, is a genetic neurodegenerative disorder that features bilateral symmetric brain calcification most prominently in the basal ganglia, thalamus, cerebellum, and subcortical white matter [4]. Among those tissues, the basal ganglia are the most likely to be affected, especially the globus

pallidus. The clinical manifestations of PFBC vary and include motor disorders, psychiatric symptoms, cognitive impairment, seizures, migraine, dizziness, and can even be asymptomatic [5]. The brain calcification of PFBC autopsy samples detected by electron microscopy indicated that deposits were composed of a mixture of glycoproteins, mucopolysaccharides, calcium salts, and iron [6].

In recent years, six pathogenic genes have been identified for PFBC: *SLC20A2*, *PDGFRB*, *PDGFB*, *XPR1*, *MYORG*, and *JAM2* [7–12]. Of the six causative genes, *SLC20A2* and *XPR1* are both phosphate transporters that play prominent roles in maintaining Ca-P homeostasis [13, 14]. *PDGFRB* and *PDGFB* encode a receptor and ligand in the mural cells (pericytes and smooth muscle cells) and endothelial cells which are associated with blood-brain barrier (BBB) integrity [15]. *MYORG*, a putative glycosidase, was specifically located in astrocytes.

[†]Miao Zhao, Xiao-Hong Lin and Yi-Heng Zeng contributed equally

*Correspondence: yaoxiangping@fjmu.edu.cn; wanjinchen75@fjmu.edu.cn

Department of Neurology, Institute of Neurology of First Affiliated Hospital, Institute of Neuroscience, and Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou 350005, China



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

[11]. Moreover, *JAM2* encodes a protein participating in a tight junction in the endothelial cells [16].

We first reported that biallelic *MYORG* mutations are the cause of autosomal recessive PFBC [11]. Clinically, PFBC patients with *MYORG* mutations mostly suffer from motor disorders (such as dysarthria, dysphagia, dystonia, parkinsonism, and ataxia), cognitive impairment, psychiatric symptoms, seizures, and dizziness. Their brain CT images consistently showed bilateral calcifications in the basal ganglia, dentate nucleus of cerebellum, subcortical white matter, and brainstem, etc. *MYORG* was originally identified from a proteomic analysis as a nuclear envelope transmembrane protein with glycosidase homology [17]. *MYORG* is also necessary for myogenic differentiation [18, 19]. We next detected that *Myorg* mRNA is largely localized to astrocytes, particularly in the Bergmann glia [11]. Brain calcification was observed in the thalamus of the *Myorg* knockout (KO) mouse model from approximately nine months of age, mimicking the phenotype in the PFBC patients. However, as a neurodegeneration progress, the *Myorg*-KO mouse models are difficult to study since brain calcification requires long observation periods, hindering the mechanistic studies of PFBC caused by loss of function of *MYORG*.

In this study, we applied a knockdown strategy to *myorg* by antisense oligonucleotides (ASO) in zebrafish. This model led to the development of calcified deposits in the brain, which could be mitigated by *myorg* cDNA supplement. In this case, the ASO-mediated knockdown strategy of *myorg* in zebrafish is another model for phenotypically and mechanistically studying PFBC, and possibly other neurodegenerative diseases.

Materials and methods

Zebrafish care and maintenance

Adult wild-type AB strain zebrafish were maintained at 28.5 °C on a 14/10 h light/dark cycle. Five to six pairs of zebrafish were paired for natural mating every generation. On average, 200–300 embryos were generated. Embryos were maintained at 28.5°C in fish water (0.2% Instant Ocean Salt in deionized water). The embryos were washed and staged according to standard procedures [20]. The zebrafish facility at Shanghai Research Center for Model Organisms is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International.

Whole-mount in situ hybridization

The primers for the *myorg* and control probes produced from cDNA of zebrafish brain are as follows: *myorg*-pb-F: 5'-ATGGGAGTATGATGATGAGGTT-3', *myorg*-pb-R: 5'-TAATACGACTCACTATAGGTTAAATGCAAG

GCACGGA-3', control-pb-F: 5'-TAATACGACTCACTA TAGGATGGGAGTATGATGATGAGGTT-3', control-pb-R: TTAAATGCAAGGCACGGA. This PCR product was transcribed for the digoxigenin (DIG)-labeled *myorg* RNA probe. The brains of adult zebrafish were isolated and fixed with 4% PFA, and used for the whole-mount in situ hybridization as previously reported [21].

qPCR analysis

Total RNA was isolated from adult zebrafish brains using the Trizol method. The RNA was reverse-transcribed to cDNA using a NovoScript® 1st Strand cDNA Synthesis SuperMix kit. qPCR was performed with a ChamQ SYBR qPCR Master Mix using Real-Time PCR System (Archimed, TMX4) with the following primers: *myorg*-RT-F: 5'-TGAAATGGTGAAGCCTAAAGAC-3', *myorg*-RT-R: 5'-CCTGTTATGAAAGGTTGGGTG-3', *efl1a*-RT-F: 5'-CTTCTCAGGCTGACTGTGC-3', *efl1a*-RT-R: 5'-CCGCTAGCATTACCCTCC-3'. The data were analyzed with the baseline of Ct values, and each sample was measured with three replicates. And the relative *myorg* mRNA level was normalized to the *efl1a*.

MO microinjections and rescue assay

Gene Tools, LLC (<http://www.gene-tools.com/>) designed the morpholino (MO). Antisense MO (Gene Tools) were microinjected into fertilized one-cell stage embryos according to standard procedures [22]. The morpholino experiments were performed according to previously reported guidelines [23]. The sequences of the *myorg* splice-blocking sequence were 5'-TAAGCACCATCC ATACTGACCTGAA-3' (*myorg*-E2I2-MO), the *myorg* translation-blocking morpholinos were 5'-AGGCAC TACCTGGTACATTCTGAAC-3' (*myorg*-ATG-MO), and the standard control morpholinos were 5'-CCT CTTACCTCAGTTACAATTTATA-3' (Control-MO). The amount of the MO used for injection was 4 ng per embryo. Total RNA was extracted from 30 to 50 embryos per group using TriPure Isolation Reagent (Roche) according to the manufacturer's instructions. RNA was reverse-transcribed to cDNA using a PrimeScript RT Reagent Kit with gDNA Eraser (Takara). Primers spanning *myorg* Exon 1 (forward primer: 5'-ACACGAAAC CAACAGTCCTC-3') and Exon 3 (reverse primer: 5'-TCCTTTGGCTTCACTGTCATAA-3') of *myorg* were used for transcript analysis to study the efficacy of the *myorg*-E2I2-MO. The primer *efl1a* sequences used as the internal control were 5'-GGAAATTCGAGACCAGCA AATAC-3' (forward) and 5'-GATACCAGCCTCAAA CTCACC-3' (reverse).

For the rescue assay, 4 ng *myorg*-E2I2-MO was co-injected with 50 pg pcDNA3.1 containing zebrafish *myorg* cDNA per embryo, respectively. The coding region of the

wild-type zebrafish *myorg* (ENS DART00000157837.2) was synthesized by Sangon Biotech and subcloned into the pcDNA3.1 vector (Invitrogen).

Calcein staining

Injected embryos were grown in 0.003% 1-phenyl-2-thiourea (PTU, Sigma, St. Louis, MO, USA) to block pigmentation and facilitate visualization until four days post-fertilization (dpf). After the treatment, zebrafish embryos (2–4 dpf) were washed three times with fish water and immersed in 0.2% calcein solution (C0875, Sigma-Aldrich) for 10 min. Next, zebrafish were thoroughly rinsed three times in fish water (5 min/wash) and anesthetized with 0.016% MS-222 (tricaine methanesulfonate, Sigma-Aldrich, St. Louis, MO, USA). The zebrafish were then oriented on their dorsal and lateral side and mounted with 3% methylcellulose (Sigma-Aldrich, St. Louis, MO, USA) in a depression slide for observation by fluorescence microscopy. The fluorescent chromophore, Calcein ($C_{30}H_{26}N_2O_{13}$), specifically binds to calcium, fluorescently staining the calcified structures in living zebrafish larvae and juveniles. This allowed us to analyze brain calcifications in live zebrafish with high sensitivity [24]. Zebrafish brain calcifications were also visible as bright green spots. The number of brain calcifications was quantitatively analyzed at different time points.

Image acquisition

Embryos and larvae were analyzed using a Nikon SMZ 1500 Fluorescence microscope and subsequently photographed with digital cameras. A subset of images was adjusted for levels, brightness, contrast, hue, and saturation with Adobe Photoshop 7.0 software (Adobe, San Jose, CA, USA) to optimally visualize the expression patterns. Positive signals were defined by manually counting the number of green punctae using Image J. Ten zebrafish for each treatment were quantified, and we calculated the averaged total signal per animal.

Statistical analysis

All data were presented as mean \pm SEM. Statistical analysis and graphical representation of the data were performed using GraphPad Prism 7.0 (GraphPad Software, San Diego, CA, USA). Statistical significance was performed using a Student's *t*-test, where appropriate. Statistical significance is indicated by * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, and **** $P < 0.0001$.

Results

myorg expression analysis in zebrafish

The *myorg* protein sequence shows about 67%~68% identity between the zebrafish and human or mice using


BLAST, which could be regarded as average to high conservation between those species. (Fig. 1A). To analyze the *myorg* expression pattern in zebrafish, we first performed the whole-mount in situ hybridization and quantitative mRNA analysis of the zebrafish brain. *myorg* mRNA was highly expressed in the cerebellum in the central nervous system (Fig. 1B, C) in zebrafish, while *myorg* was most highly expressed in the muscle in the peripheral tissues (Fig. 1C). Also, *myorg* mRNA exhibited relative abundant expression in the hypothalamus, medulla oblongata, eyes, kidney, and intestine, but had low expression levels in the heart (Fig. 1C; Additional file 1: Table S1). The *myorg* expression pattern in zebrafish was similar to that of mice, especially in the brain [11].

As the Expression Atlas database (<https://www.ebi.ac.uk/gxa/home>) displayed, *myorg* is highly expressed in the development periods from blastula to larval day 5 except for few stages (like segmentation 14–17 somites and pharyngula prim-25) (Additional file 1: Fig. S1). A single-cell transcriptome atlas for zebrafish development suggested that the distribution of *myorg* RNA ranged from different cell types, including neuroblasts, neuron, cranial neural crest, and glial cells [25]. Collectively, *myorg* expressed broadly in the brain of zebrafish, including the critical regions, stages, and cell types.

Calcification deposits in *myorg* knockdown zebrafish


We previously found that *Myorg*-KO mice could develop brain calcifications in the thalamus when they were nine months old. To examine the loss-of-function effect of *myorg* in zebrafish, we designed and injected zebrafish with an antisense oligo targeting Exon 2 and Intron 2 (E2I2-MO) of *myorg* to block its splicing sites (Fig. 2Aa). The effectiveness of *myorg* knockdown was confirmed by PCR of cDNA after morpholino injection of zebrafish larvae at 2 dpf (Fig. 2B). As a comparison, *e1fa* showed similar transcript abundance under both the *myorg*-E2I2-MO and Control-MO intervention (Fig. 2B). Sanger sequencing also validated that E2I2-MO resulted in a complete skipping of Exon 2 in the transcript (Fig. 2C), leading to a knockdown of *myorg* in zebrafish. We also utilized another morpholino targeting the start codon of *myorg* (ATG-MO), in order to prevent the protein expression by blocking its translation initiation (Fig. 2Ab).

We observed the calcifications in the head of *myorg* knockdown zebrafish before skeletal formation around 5 dpf using calcein, a calcium-binding fluorescent chromophore. The fluorescent chromophore, calcein ($C_{30}H_{26}N_2O_{13}$), specifically binds to calcium, fluorescently staining the calcified structures and allowing for highly sensitive analysis of brain calcifications in live zebrafish larvae [24]. After microinjection of the *myorg*-E2I2-MO and *myorg*-ATG-MO into fertilized



one-cell stage embryos, the calcification number in the *myorg*-knockdown zebrafish brain was 35.6 (11–80) and 10.6 (9–13), respectively, compared to the control group value of 1.1 (0–2) in 3 dpf zebrafish (Fig. 2D, E; Table 1). The number of brain calcification deposits caused by *myorg*-E2I2-MO were more than that by *myorg*-ATG-MO. We also observed that the number of green fluorescent signals was consistently increased during 2–4

dpf after microinjection of the *myorg*-E2I2-MO, while the size of calcification nodules was uniform (Fig. 2F). Indeed, the *myorg*-knockdown zebrafish became weak after *myorg*-E2I2-MO and *myorg*-ATG-MO injection, and they could not survive longer than about one week. Collectively, we confirmed that calcified deposits developed in the *myorg* knockdown zebrafish brains before 5 dpf using two kinds of morpholino-mediated strategies.



myorg cDNA rescued the E2I2-MO induced brain calcification

To verify the calcification phenotype using *myorg*-knockdown strategies in zebrafish, we performed the

rescue assay to confirm its accuracy. We synthesized the *myorg* cDNA and cloned it into the pcDNA3.1 vector, then co-injected it, along with *myorg*-E2I2-MO, into zebrafish embryos. Compared to the *myorg*-E2I2-MO


Table 1 Number of calcification nodules in *myorg* knockdown zebrafish at 3 dpf (10 embryos for each group)

	Control-MO (N=10)	<i>myorg</i> -E2I2-MO (N=10)	<i>myorg</i> -ATG-MO (N=10)
Number of brain calcification nodules	0	52	10
	2	39	11
	1	63	13
	1	80	11
	2	11	10
	2	20	9
	1	40	12
	1	15	11
	0	15	10
	1	21	9
Mean	1.1	35.6	10.6
SEM	0.2333	7.403	0.4

alone, administering E2I2-MO and *myorg* cDNA plasmid decreased calcification deposits at 3 dpf (Fig. 3A, B). Based on E2I2-MO knockdown, the number of calcification nodules is around 1.7 (0–3) after *myorg* cDNA replenishment, which is close to the effect resulting from Control-MO (Fig. 3B). In conclusion, our data confirmed that knockdown of *myorg* in zebrafish could develop brain calcification, and this phenotype could be mitigated by *myorg* cDNA compensation.

Discussion

The specific function of MYORG in PFBC remains unclear, meaning that animal models simulating PFBC-like brain calcifications could help elucidate the mechanism of PFBC and relevant therapies. In this study, we demonstrate that knockdown of *myorg* in zebrafish by ASO could successfully mimic the brain calcification phenotype, which could serve as another animal model for assessing MYORG-associated brain calcification.



Of the six causative genes, we reported that *MYORG* was the first and most prevalent pathogenic gene in autosomal recessive PFBC [26, 27]. Gene knockout mice were mostly used to mimic the phenotype of PFBC patients. However, neurodegenerative disorders progress relatively slowly, which extends the time required to observe phenotypes such as brain calcifications. Using histological staining, *Slc20a2*-KO mice exhibited relatively obvious calcified nodules at 15 weeks old, which is one of the earliest emerging PFBC mouse models [28]. Similarly, the *Pdgfrb*^{ret/ret} mice developed brain calcifications at two months old [9]. We observed the calcified deposits in the thalamus around the nine months old in *Myorg*-KO mice [11]. Nevertheless, no obvious brain calcification phenotypes were present in the *Pdgfrb* and *Jam2* knockout mouse models until they were 14 and 18 months old, respectively [16, 29]. To some extent, our *myorg*-knockdown zebrafish could mimic the brain calcification phenotype at an early age before skull formation, which could accelerate the emergence of the diagnostic phenotype and facilitate mechanistic studies.

Zebrafish can be used to simulate disease-associated phenotypes in mammalian species [30–32]. Using zebrafish as a model has several advantages, including their small size, easy maintenance, fast growth, and short generational time, etc. In particular, embryo zebrafish appear to be transparent, which is advantageous for monitoring the development or pathogenic states of certain organs, such as the complicated central nervous system (CNS), while zebrafish also provide a tractable system for measuring certain behaviors [33]. To date, zebrafish have been used to explore CNS disorders, including autism spectrum disorders, cerebrovascular disorders, neuromuscular diseases, epilepsy, hereditary spastic paraplegia, and neurodegenerative diseases [34–39]. Our findings indicate that brain calcification deposits could be detected in the zebrafish embryos before the skeletal system forms, which could make them a complementary model similar to above-mentioned PFBC mouse models.

Gene knockdown has been widely used to mimic clinical phenotypes in zebrafish [22], especially the antisense oligo blocking strategy. In comparison, gene knockout zebrafish models have been demonstrated to produce genetic compensation response (GCR), which depends on premature termination codons or the homology of transgene sequence with the compensatory endogenous genes [40]. Alleles that are transcribed in response to the deleterious mutation could display more severe phenotypes than alleles with mutant mRNA decay since they can escape the transcriptional adaptation [41]. Morpholino delivery to zebrafish can rapidly model

the disease phenotype and potentially avoid the phenotype discrepancies. Knockdown zebrafish models have been used to successfully mimic the typical phenotypes of neutrophil defect syndrome, early-onset stroke and vasculopathy, cerebral small-vessel disease, macular degeneration, adolescent idiopathic scoliosis, and limb-girdle muscular dystrophy [36, 37, 42–45]. We applied the ASO strategy to zebrafish zygotes and observed multiple calcified nodules in the brain parenchyma of *myorg* knockdown zebrafish, and the calcification nodules were persistent at least in 2–4 dpf, successfully modeling the PFBC phenotype. We also rescued the phenotype by supplementing the *myorg* cDNA, which served as a key control to validate the fidelity of brain calcification in *myorg*-knockdown zebrafish. However, the knockdown strategy also has limitations, for example, ASO knockdown effects cannot be steadily passed on to its offspring, and the *myorg*-knockdown zebrafish could not survive more than one week because of the inability to obtain feed. This hinders us from continuously tracking the pathogenic characteristics.

Conventional calcification detection methods have used histochemical stainings including Alcian blue, Alizarin red, and Von Kossa. The widespread calcification in vasculature could be observed in the α -klotho knockout zebrafish at five months old [46]. However, it is also confirmed that Alcian blue and Alizarin red are not sensitive enough to recognize the calcified bone structure in zebrafish embryos [24]. Our *myorg* knockdown larval zebrafish is more fragile with PFA fixing when prepared for immunohistochemical staining, which hinders us from recognizing their physical structures. Accordingly, the results were not stable. Compared to the above two bone markers, calcein staining is more convenient, inclusive, and accurate without toxicity in a live state.

In summary, we established zebrafish as a novel model to simulate brain calcifications in animals other than mice. Our results demonstrate that knockdown of *myorg* by ASO could lead to calcification in the brain of zebrafish embryos. This could promote further study of the molecular mechanisms and precise therapies for PFBC.

Abbreviations

PFBC: Primary familial brain calcification; dpf: Days post-fertilization; ASO: Antisense oligonucleotides; BBB: Blood–brain barrier; CNS: Central nervous system; GCR: Genetic compensation response.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13041-022-00953-4>.

Additional file 1: Fig. S1. *myorg* expression of zebrafish in different developing stages (<https://www.ebi.ac.uk/gxa/home>). **Table S1.** The mean Ct

values for *myorg* and *ef1a* mRNA expression in different regions of adult zebrafish.

Acknowledgements

Not applicable.

Author contributions

WJC, XPY, and MZ designed and supervised the study, and drafted the manuscript. WJC critically revised the important intellectual content of the manuscript. MZ, XHL, and YHZ generated and collected data, designed and made diagrams, and performed analyses and interpretation. HZS, CW, KY, YKC, and BWL collected data and provided technical support. The final version of the manuscript was approved by all authors. All authors read and approved the final manuscript.

Funding

This work was supported by the grants 82025012 (W.-J.C.), U1905210 (W.-J.C.) 82171841 (X.-P.Y.), and 81901158 (C.W.) from the National Natural Science Foundation of China, the Natural Science Foundation of Fujian Province 2019J02010 (W.-J.C.) and 2021J01221 (M.Z.), the Joint Funds for the Innovation of Science and Technology, Fujian Province 2020Y9118 (X.-P.Y.), China Postdoctoral Science Foundation 2022M710704 (M.Z.), the Post-doctoral Startup Fund for Scientific Research of the First Affiliated Hospital of Fujian Medical University BSH3606 (M.Z.), and the Scientific Research Foundation for the Introduction of Talent of the First Affiliated Hospital of Fujian Medical University (M.Z.).

Availability of data and materials

All experimental protocols are described in the "Materials and methods" section or in the references therein, and resources are available upon request from the corresponding authors XPY and WJC.

Declarations

Ethics approval and consent to participate

This study was approved by the Institutional Ethics Committee of the First Affiliated Hospital of Fujian Medical University (MRCTA, ECFAH of FMU [2019]198).

Consent for publication

Not applicable.

Competing interests

The authors declare no competing or financial interests.

Received: 14 October 2021 Accepted: 9 July 2022

Published online: 23 July 2022

References

- Mann DMA. Calcification of the basal ganglia in Down's syndrome and Alzheimer's disease. *Acta Neuropathol.* 1988;76:595–8.
- Vermersch P, Leys D, Pruvo JP, Clarisse J, Petit H. Parkinson's disease and basal ganglia calcifications: prevalence and clinico-radiological correlations. *Clin Neurol Neurosurg.* 1992;94:213–7.
- Chen S, Cen Z, Fu F, Chen Y, Chen X, Yang D, et al. Underestimated disease prevalence and severe phenotypes in patients with biallelic variants: a cohort study of primary familial brain calcification from China. *Park Relat Disord.* 2019;64:211–9.
- Quintáns B, Oliveira J, Sobrido MJ. Primary familial brain calcifications. *Handb Clin Neurol.* 2018;147:307–17.
- Nicolas G, Pottier C, Charbonnier C, Guyant-Maréchal L, Le Ber I, Pariente J, et al. Phenotypic spectrum of probable and genetically-confirmed idiopathic basal ganglia calcification. *Brain.* 2013;136:3395–407.
- Kobayashi S, Yamadori I, Miki H, Ohmori M. Idiopathic nonarteriosclerotic cerebral calcification (Fahr's disease): an electron microscopic study. *Acta Neuropathol.* 1987;73:62–6.
- Wang C, Li Y, Shi L, Ren J, Patti M, Wang T, et al. Mutations in SLC20A2 link familial idiopathic basal ganglia calcification with phosphate homeostasis. *Nat Genet.* 2012;44:254–6.
- Nicolas G, Pottier C, Maltête D, Coutant S, Rovelet-Lecrux A, Legallic S, et al. Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia calcification. *Neurology.* 2013;80:181–7.
- Keller A, Westenberger A, Sobrido MJ, García-Murias M, Domingo A, Sears RL, et al. Mutations in the gene encoding PDGF-B cause brain calcifications in humans and mice. *Nat Genet.* 2013;45:1077–82.
- Legati A, Giovannini D, Nicolas G, López-Sánchez U, Quintáns B, Oliveira JRM, et al. Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export. *Nat Genet.* 2015;47:579–81.
- Yao XP, Cheng X, Wang C, Zhao M, Guo XX, Su HZ, et al. Biallelic mutations in MYORG cause autosomal recessive primary familial brain calcification. *Neuron.* 2018;98:1116–1123.e5.
- Cen Z, Chen Y, Chen S, Wang H, Yang D, Zhang H, et al. Biallelic loss-of-function mutations in JAM2 cause primary familial brain calcification. *Brain.* 2020;143:491–502.
- Wallingford MC, Chia JJ, Leaf EM, Borgeia S, Chavkin NW, Sawangmake C, et al. SLC20A2 deficiency in mice leads to elevated phosphate levels in cerebrospinal fluid and glymphatic pathway-associated arteriolar calcification, and recapitulates human idiopathic Basal Ganglia calcification. *Brain Pathol.* 2017;27:64–76.
- Giovannini D, Touhami J, Charnet P, Sitbon M, Battini JL. Inorganic phosphate export by the retrovirus receptor XPR1 in metazoans. *Cell Rep.* 2013;3:1866–73.
- Betsholtz C, Keller A. PDGF, pericytes and the pathogenesis of idiopathic basal ganglia calcification (IBGC). *Brain Pathol.* 2014;24:387–95.
- Schottlaender LV, Abeti R, Jaunmuktane Z, Macmillan C, Chelban V, O'Callaghan B, et al. Bi-allelic JAM2 variants lead to early-onset recessive primary familial brain calcification. *Am J Hum Genet.* 2020;106:412–21.
- Schirmer EC, Florens L, Guan T, Yates JR, Gerace L. Nuclear membrane proteins with potential disease links found by subtractive proteomics. *Science.* 2003;301:1380–2.
- Chen IHB, Huber M, Guan T, Bubeck A, Gerace L. Nuclear envelope transmembrane proteins (NETs) that are up-regulated during myogenesis. *BMC Cell Biol.* 2006;7:1–16.
- Datta K, Guan T, Gerace L. NET37, a nuclear envelope transmembrane protein with glycosidase homology, is involved in myoblast differentiation. *J Biol Chem.* 2009;284:29666–76.
- Kimmel CB, Ballard WW, Kimmel SR, Ullmann B, Schilling TF. Stages of embryonic development of the zebrafish. *Dev Dyn.* 1995;203:253–310.
- Thisse B, Heyer V, Lux A, Alunni V, Degrave A, Selliez I, et al. Spatial and temporal expression of the zebrafish genome by large-scale in situ hybridization screening. *Methods Cell Biol.* 2004;77:505–19.
- Nasevicius A, Ekker SC. Effective targeted gene "knockdown" in zebrafish. *Nat Genet.* 2000;26:216–20.
- Stainier DYR, Raz E, Lawson ND, Ekker SC, Burdine RD, Eisen JS, et al. Guidelines for morpholino use in zebrafish. *PLoS Genet.* 2017;13:6–10.
- Jun Du S, Frenkel V, Zohar Y, Kindschi G. Visualizing normal and defective bone development in zebrafish embryos using the fluorescent chromophore calcein. *Dev Biol.* 2001;238:239–46.
- Farnsworth DR, Saunders LM, Miller AC. A single-cell transcriptome atlas for zebrafish development. *Dev Biol.* 2020;459:100–8.
- Alvarez-Fischer D, Westenberger A. Biallelic MYORG mutations: primary familial brain calcification goes recessive. *Mov Disord.* 2019;34:322.
- Bauer M, Rahat D, Zisman E, Tabach Y, Lossos A, Meiner V, et al. MYORG mutations: a major cause of recessive primary familial brain calcification. *Curr Neurol Neurosci Rep.* 2019;19:70.
- Jensen N, Schröder HD, Hejbøl EK, Thomsen JS, Brühl A, Larsen FT, et al. Mice knocked out for the primary brain calcification-associated gene Slc20a2 show unimpaired prenatal survival but retarded growth and nodules in the brain that grow and calcify over time. *Am J Pathol.* 2018;188:1865–81.
- Vanlandewijck M, Lebouvier T, Mäe MA, Nahar K, Hornemann S, Kenkel D, et al. Functional characterization of germline mutations in PDGFB and PDGFRB in primary familial brain calcification. *PLoS ONE.* 2015;10:1–25.
- Santoriello C, Zon LI. Hooked! modeling human disease in zebrafish. *J Clin Invest.* 2012;122:2337–43.
- Zon LI, Peterson RT. In vivo drug discovery in the zebrafish. *Nat Rev Drug Discov.* 2005;4:35–44.

32. Lieschke GJ, Currie PD. Animal models of human disease: zebrafish swim into view. *Nat Rev Genet.* 2007;8:353–67.
33. Fontana BD, Mezzomo NJ, Kalueff AV, Rosemberg DB. The developing utility of zebrafish models of neurological and neuropsychiatric disorders: a critical review. *Exp Neurol.* 2018;299:157–71.
34. Meshalkina DA, Kizlyk N, Kysil MV, Collier E, Echevarria AD, Abreu DJ, et al. Zebrafish models of autism spectrum disorder. *Exp Neurol.* 2018;299:207–16.
35. Lin X, Su HZ, Dong EL, Lin XH, Zhao M, Yang C, et al. Stop-gain mutations in UBAP1 cause pure autosomal-dominant spastic paraplegia. *Brain.* 2019;142:2238–52.
36. Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. *N Engl J Med.* 2014;370:911–20.
37. Carss KJ, Stevens E, Foley AR, Cirak S, Riemersma M, Torelli S, et al. Mutations in GDP-mannose pyrophosphorylase B cause congenital and limb-girdle muscular dystrophies associated with hypoglycosylation of α -dystroglycan. *Am J Hum Genet.* 2013;93:29–41.
38. Xi Y, Noble S, Ekker M. Modeling neurodegeneration in zebrafish. *Curr Neurol Neurosci Rep.* 2011;11:274–82.
39. Grone BP, Baraban SC. Animal models in epilepsy research: legacies and new directions. *Nat Neurosci.* 2015;18:339–43.
40. Ma Z, Zhu P, Shi H, Guo L, Zhang Q, Chen Y, et al. PTC-bearing mRNA elicits a genetic compensation response via Upf3a and COMPASS components. *Nature.* 2019;568:259–63.
41. El-Brolosy MA, Kontarakis Z, Rossi A, Kuenne C, Günther S, Fukuda N, et al. Genetic compensation triggered by mutant mRNA degradation. *Nature.* 2019;568:193–7.
42. Vilboux T, Lev A, Malicdan MCV, Simon AJ, Järvinen P, Racek T, et al. A congenital neutrophil defect syndrome associated with mutations in VPS45. *N Engl J Med.* 2013;369:54–65.
43. French C, Seshadri S, Destefano A, Fornage M, Arnold C, Gage P, et al. Mutation of FOXC1 and PITX2 induces cerebral small-vessel disease. *Clin J.* 2014;124:4877–81.
44. Van De Ven JPH, Nilsson SC, Tan PL, Buitendijk GHS, Ristau T, Mohlin FC, et al. A functional variant in the CFI gene confers a high risk of age-related macular degeneration. *Nat Genet.* 2013;45:813–7.
45. Kou I, Takahashi Y, Johnson TA, Takahashi A, Guo L, Dai J, et al. Genetic variants in GPR126 are associated with adolescent idiopathic scoliosis. *Nat Genet.* 2013;45:676–9.
46. Singh AP, Sosa MX, Fang J, Shanmukhappa SK, Hubaud A, Fawcett CH, et al. α Klotho regulates age-associated vascular calcification and lifespan in zebrafish. *Cell Rep.* 2019;28:2767–2776.e5.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

